Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage

Andy Yu, Brad Jones, Ningjie Hu, Hong Chang, Sidrah Ahmad, Jun Liu, Mark Parrington, Mario Ostrowski

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The poxviruses including canarypox (ALVAC) and vaccinia viruses are promising vaccine vectors in humans, but little is known about their biology in human cells. Using recombinant enhanced green fluorescence protein (EGFP)-expressing ALVAC and vaccinia viruses, we have focused here on a side-by-side comparison of ALVAC and vaccinia virus tropism for cells from human peripheral blood and bone marrow. Both ALVAC and vaccinia viruses showed a strong bias towards monocyte infection. ALVAC minimally infected CD19+ B cells and was unable to infect ex vivo NK cells and T lymphocytes, whereas vaccinia virus could infect B lymphocytes and NK cell populations. Vaccinia virus was also able to infect T lymphocytes at low, but detectable levels that could be enhanced upon their activation. The observed preferential infection of ALVAC or vaccinia virus to monocytes was the result of preferential binding to this population, rather than lineage-specific differences in the expression of viral genes. Moreover, the level of CD14 expression on monocytes correlated with their preference to be infected with ALVAC or vaccinia virus. Both ALVAC and vaccinia viruses could infect immature monocyte derived dendritic cells (MDDCs), but only ALVAC infection induced their subsequent maturation. Vaccinia virus, however, showed greater tropism for mature MDDCs compared to ALVAC. Infection in human bone marrow cultures showed that ALVAC infection was restricted to a myelomonocytoid cell-specific CD33+ cell population, while vaccinia virus showed a strong, but not exclusive, preference for these cells. These findings have implications in terms of choosing optimal pox virus derived vectors as vaccines in terms of reducing clinical reactogenicity and inducing dendritic cell (DC) maturation.

Original languageEnglish (US)
Pages (from-to)6376-6391
Number of pages16
JournalVaccine
Volume24
Issue number40-41
DOIs
StatePublished - Sep 29 2006
Externally publishedYes

Fingerprint

Canarypox virus
Vaccinia virus
tropisms
Tropism
Cell Lineage
monocytes
Monocytes
cells
dendritic cells
Dendritic Cells
Infection
infection
natural killer cells
Natural Killer Cells
bone marrow
B-lymphocytes
B-Lymphocytes
Vaccines
T-lymphocytes
Bone Marrow

Keywords

  • ALVAC
  • Dendritic cell
  • Monocyte
  • Myeloid cell
  • Vaccinia
  • Virus

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. / Yu, Andy; Jones, Brad; Hu, Ningjie; Chang, Hong; Ahmad, Sidrah; Liu, Jun; Parrington, Mark; Ostrowski, Mario.

In: Vaccine, Vol. 24, No. 40-41, 29.09.2006, p. 6376-6391.

Research output: Contribution to journalArticle

Yu, Andy ; Jones, Brad ; Hu, Ningjie ; Chang, Hong ; Ahmad, Sidrah ; Liu, Jun ; Parrington, Mark ; Ostrowski, Mario. / Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. In: Vaccine. 2006 ; Vol. 24, No. 40-41. pp. 6376-6391.
@article{e002e4486aff4f479c997a903e402097,
title = "Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage",
abstract = "The poxviruses including canarypox (ALVAC) and vaccinia viruses are promising vaccine vectors in humans, but little is known about their biology in human cells. Using recombinant enhanced green fluorescence protein (EGFP)-expressing ALVAC and vaccinia viruses, we have focused here on a side-by-side comparison of ALVAC and vaccinia virus tropism for cells from human peripheral blood and bone marrow. Both ALVAC and vaccinia viruses showed a strong bias towards monocyte infection. ALVAC minimally infected CD19+ B cells and was unable to infect ex vivo NK cells and T lymphocytes, whereas vaccinia virus could infect B lymphocytes and NK cell populations. Vaccinia virus was also able to infect T lymphocytes at low, but detectable levels that could be enhanced upon their activation. The observed preferential infection of ALVAC or vaccinia virus to monocytes was the result of preferential binding to this population, rather than lineage-specific differences in the expression of viral genes. Moreover, the level of CD14 expression on monocytes correlated with their preference to be infected with ALVAC or vaccinia virus. Both ALVAC and vaccinia viruses could infect immature monocyte derived dendritic cells (MDDCs), but only ALVAC infection induced their subsequent maturation. Vaccinia virus, however, showed greater tropism for mature MDDCs compared to ALVAC. Infection in human bone marrow cultures showed that ALVAC infection was restricted to a myelomonocytoid cell-specific CD33+ cell population, while vaccinia virus showed a strong, but not exclusive, preference for these cells. These findings have implications in terms of choosing optimal pox virus derived vectors as vaccines in terms of reducing clinical reactogenicity and inducing dendritic cell (DC) maturation.",
keywords = "ALVAC, Dendritic cell, Monocyte, Myeloid cell, Vaccinia, Virus",
author = "Andy Yu and Brad Jones and Ningjie Hu and Hong Chang and Sidrah Ahmad and Jun Liu and Mark Parrington and Mario Ostrowski",
year = "2006",
month = "9",
day = "29",
doi = "10.1016/j.vaccine.2006.06.011",
language = "English (US)",
volume = "24",
pages = "6376--6391",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "40-41",

}

TY - JOUR

T1 - Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage

AU - Yu, Andy

AU - Jones, Brad

AU - Hu, Ningjie

AU - Chang, Hong

AU - Ahmad, Sidrah

AU - Liu, Jun

AU - Parrington, Mark

AU - Ostrowski, Mario

PY - 2006/9/29

Y1 - 2006/9/29

N2 - The poxviruses including canarypox (ALVAC) and vaccinia viruses are promising vaccine vectors in humans, but little is known about their biology in human cells. Using recombinant enhanced green fluorescence protein (EGFP)-expressing ALVAC and vaccinia viruses, we have focused here on a side-by-side comparison of ALVAC and vaccinia virus tropism for cells from human peripheral blood and bone marrow. Both ALVAC and vaccinia viruses showed a strong bias towards monocyte infection. ALVAC minimally infected CD19+ B cells and was unable to infect ex vivo NK cells and T lymphocytes, whereas vaccinia virus could infect B lymphocytes and NK cell populations. Vaccinia virus was also able to infect T lymphocytes at low, but detectable levels that could be enhanced upon their activation. The observed preferential infection of ALVAC or vaccinia virus to monocytes was the result of preferential binding to this population, rather than lineage-specific differences in the expression of viral genes. Moreover, the level of CD14 expression on monocytes correlated with their preference to be infected with ALVAC or vaccinia virus. Both ALVAC and vaccinia viruses could infect immature monocyte derived dendritic cells (MDDCs), but only ALVAC infection induced their subsequent maturation. Vaccinia virus, however, showed greater tropism for mature MDDCs compared to ALVAC. Infection in human bone marrow cultures showed that ALVAC infection was restricted to a myelomonocytoid cell-specific CD33+ cell population, while vaccinia virus showed a strong, but not exclusive, preference for these cells. These findings have implications in terms of choosing optimal pox virus derived vectors as vaccines in terms of reducing clinical reactogenicity and inducing dendritic cell (DC) maturation.

AB - The poxviruses including canarypox (ALVAC) and vaccinia viruses are promising vaccine vectors in humans, but little is known about their biology in human cells. Using recombinant enhanced green fluorescence protein (EGFP)-expressing ALVAC and vaccinia viruses, we have focused here on a side-by-side comparison of ALVAC and vaccinia virus tropism for cells from human peripheral blood and bone marrow. Both ALVAC and vaccinia viruses showed a strong bias towards monocyte infection. ALVAC minimally infected CD19+ B cells and was unable to infect ex vivo NK cells and T lymphocytes, whereas vaccinia virus could infect B lymphocytes and NK cell populations. Vaccinia virus was also able to infect T lymphocytes at low, but detectable levels that could be enhanced upon their activation. The observed preferential infection of ALVAC or vaccinia virus to monocytes was the result of preferential binding to this population, rather than lineage-specific differences in the expression of viral genes. Moreover, the level of CD14 expression on monocytes correlated with their preference to be infected with ALVAC or vaccinia virus. Both ALVAC and vaccinia viruses could infect immature monocyte derived dendritic cells (MDDCs), but only ALVAC infection induced their subsequent maturation. Vaccinia virus, however, showed greater tropism for mature MDDCs compared to ALVAC. Infection in human bone marrow cultures showed that ALVAC infection was restricted to a myelomonocytoid cell-specific CD33+ cell population, while vaccinia virus showed a strong, but not exclusive, preference for these cells. These findings have implications in terms of choosing optimal pox virus derived vectors as vaccines in terms of reducing clinical reactogenicity and inducing dendritic cell (DC) maturation.

KW - ALVAC

KW - Dendritic cell

KW - Monocyte

KW - Myeloid cell

KW - Vaccinia

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=33748465749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748465749&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.06.011

DO - 10.1016/j.vaccine.2006.06.011

M3 - Article

C2 - 16859816

AN - SCOPUS:33748465749

VL - 24

SP - 6376

EP - 6391

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 40-41

ER -